ABSTRACT
Inflammatory diseases, including cancer, hypertension, and inflammatory bowel disease (IBD), pose significant challenges in modern medicine due to limitations associated with conventional therapies, such as low bioavailability, systemic side effects, and inadequate targeting of diseased tissues. Nanotechnology has emerged as a promising solution to these challenges, offering innovative drug delivery systems that enhance therapeutic efficacy while minimizing adverse effects. In cancer treatment, nanoparticles facilitate targeted drug delivery, improve chemotherapeutic retention in tumors, and enhance radiation therapy, thereby reducing damage to healthy tissues. Additionally, nanotechnology enables the development of immunotherapeutic strategies, including nanoparticle-based vaccines that stimulate the immune system to recognize and eliminate cancer cells. In hypertension management, nanoformulations, such as nanoemulsions, solid lipid nanoparticles, and dendrimers, improve the solubility and bioavailability of antihypertensive drugs, leading to enhanced therapeutic outcomes and sustained drug release. Similarly, in IBD, nanocarrier-based systems allow for localized drug delivery to inflamed intestinal tissues, reducing systemic absorption and improving treatment precision. The primary objective of nanoformulations is to optimize drug delivery by increasing bioavailability, targeting specific disease sites, and reducing adverse effects. As research continues to advance, nanotechnology-based therapies are expected to revolutionize the treatment of inflammatory diseases by offering safer, more effective, and long-lasting treatment options. These innovations hold great potential for improving patient outcomes and transforming the future of medicine.
References
- [1] Laroui, H., Wilson, D.S., Dalmasso, G., Salaita, K., Murthy, N. and Sitaraman, SV. (2011). Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol, 300: G371–83
- [2] Haleema, A., Javaid, M., Singh, RP., Rab, S., Suman, R. (2023). Applications of nanotechnology in medical field: a brief review. Global Health Journal,7:70–77 https://doi.org/10.1016/j.glohj.2023.02.008
- [3] De Jong, W.H., Borm, P.J. (2008). Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine; 3:133–49
- [4] Nikalje, A.P. (2015). Nanotechnology and its Applications in Medicine. Med chem 5: 081-089. Wolfram, S. 2002. A New Kind of Science. Wolfram Media, Inc. p. 1193
- [5] Polizu, S., Savadogo, O., Poulin, P., Yahia, L.H. (2006). Applications of carbon nanotubes-based biomaterials in biomedical nanotechnology. J Nanosci Nanotechnol, 6(7):1883-1904.
- [6] Ren, C., Wang, Z., Zhang, X., et al. (2021). Construction of all-in-one peptide nanomedicine with photoacoustic imaging-guided mild hyperthermia for enhanced cancer chemotherapy. Chem Eng J, 405:127008
- [7] Lacoeuille, F., Garcion, E., Benoit, J.P, Lamprecht, A. (2007). Lipid nanocapsules for intracellular drug delivery of anticancer drugs. J Nanosci Nanotechnol; 7:4612–7
- [8] Tabata, Y., Inoue, Y., Ikada, Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14:1677–85
- [9] Tamura, A., Ozawa, K., Ohya, T., Tsuyama, N., Eyring, E.M., Masujima, T. (2006). Nanokinetics of drug molecule transport into a single cell. Nanomedicine, 1:345–50
- Jung, , Kamm, W., Breitenbach, A., Kaiserling, E., Xiao, J.X. and Kissel, T. (2000). Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm, 50:147–60.
Download all article in PDF
